Ropes & Gray represented Blackstone Life Sciences in a research and development co-funding agreement with Johnson & Johnson. Under the agreement, Johnson & Johnson and funds managed by Blackstone Life Sciences will jointly finance a portion of the ongoing and future clinical trials of bleximenib (JNJ-75276617), an investigational oral menin inhibitor, for acute myeloid leukemia. The transaction was announced on February 23.
The Ropes & Gray team was led by life sciences licensing partner Abigail Gregor and associate James Gould, and included IP transactions partner Melissa Rones, tax partner Pamela Glazier, IP transactions counsel Ryan Murphey, and technical advisor Giulia Schukraft.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.